This educational supplement has been created to educate healthcare professionals on the safe and proper use of Extended-Release (ER) and Long-Acting (LA) opioids for chronic pain management. Opioids are the cornerstone of modern pain management. They are highly complex molecules which require knowledge and integration of basic science, clinical, pharmacological, psychosocial, abuse, diversion, and public health aspects of opioids. This Opioid Risk Evaluation and Mitigation Strategy (REMS) supplement is a valuable tool that can be utilized daily by everyone in your practice. Continuing Medical Education (CME/CE) credits are available for studying this supplement and completing the online test. The supplement and test can be completed in a little more than three hours, but it will have a lifetime benefit!
Featured Courses for 2017
The Global Learning Center provides you with free access to the latest peer-reviewed clinical information related to the treatment of patients with rheumatoid arthritis (RA). The RA Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles, and other resources to healthcare providers who treat patients with RA.
This CME-accredited Clinical Research UpdatesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the identification, evaluation, and treatment of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate the latest evidence for severe asthma phenotypes, the clinical utility of various disease biomarkers, and the profiles of current and emerging biologic therapies, with a focus on individualizing treatment plans. Faculty also incorporate the perspectives of patients with asthma, including the burdens of severe disease, hidden challenges to good long-term outcomes, and the benefits of shared decision-making.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017Format: Conference Report
The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
In this Clinical Issues™ program, faculty with expertise in clinical immunology and pulmonology will discuss and debate a series of topics related to the evaluation and long-term treatment of patients with severe asthma. The faculty panel will provide their insights into severe asthma classification, biomarkers, comorbidity management, and current and emerging targeted biologic therapies, all shaped by the latest evidence presented at the American Thoracic Society’s 113th Annual International Conference. Attendees are sure to leave this lively and engaging program with new information and a fresh perspective on the evolving management paradigms in severe asthma.
Tuesday, May 23, 2017
6:30 PM-8:30 PM
Washington Marriott at Metro Center
Junior Ballroom (Floor 2)
Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.
This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.
This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.
This symposium archive will provide participants with the opportunity to assess remaining challenges in the care of patients with spasticity. In addition to reviewing appropriate use of chemodenervation and other treatments, this activity will also highlight techniques for improved communication between physicians and patients regarding the causes of functional impairments, individualized treatment options, customized goals of treatment, and the need for post-intervention rehabilitation and home programs via interactive video case presentations.
The content for this activity is based on the satellite symposium, Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases, that was presented at the AAPM&R Annual Assembly in New Orleans, Louisiana on October 22, 2016.
The content for this activity is based on the satellite symposium, “Joining a Conversation on Improving the Multidisciplinary Management of SMA: Now and in the Future”, that was presented at the 45th Child Neurology Society Annual Meeting in Vancouver, Canada, on October 27, 2016.
This presentation will provide an overview of the clinical picture of SMA and its natural history, offer guidance on the diagnosis and classification of SMA by neurological examination and gene profiling, discuss the appropriate use of available assessment tools and outcomes measures, and review the emerging treatment landscape via the latest scientific data. Using interactive plenary sessions and selected patient case presentations, our expert panel will encourage the exchange of views and opinions on the rapidly evolving SMA treatment landscape.
Alzheimer’s Disease in Primary Care: The Significance of Early Detection, Diagnosis, and InterventionFormat: Webcast
The field of Alzheimer’s disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.
AHA 2016: An Update of Emerging Therapeutics to Prevent Stroke in Patients with Non-Valvular Atrial FibrillationFormat: Medical Meeting Reporter
This Official Elsevier Meeting Reporter will highlight recent science and clinical strategies for the management of patients with atrial fibrillation presented at the American Heart Association Scientific Sessions 2016 held in New Orleans, Louisiana. Expert faculty will discuss anticoagulant management, including prevention, diagnostic criteria and current treatment options. Updates on existing tactics for preventing stroke in the population of patients with atrial fibrillation will also be covered in the duration of this discussion-based activity. Faculty will relay optimal methods for educating newly diagnosed individuals and improving patient-physician communication lines as treatment progresses. Upon completion of this program, learners will find themselves better acquainted with the current science needed for accurate diagnosis as well as quality of life improvement in patients with atrial fibrillation.
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and TreatmentFormat: Webcast
The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.
Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic FibrosisFormat: Webcast
The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.
The treatment of HCV has undergone a dramatic evolution in the last several years. Whereas traditional interferon-based therapy for HCV was limited by poor efficacy and a heavy burden of side effects, interferon-free antiviral regimens are now available, offering new options for patients and altering the approach to this serious disease. The rapid pace of drug research, development, and approval requires frequent updates to treatment guidelines and leaves many clinicians wondering when, in whom, and how to manage chronic HCV infection.
Insulin has been used as a standard treatment for patients with diabetes for almost 100 years. Over time, advances in insulin development have improved its pharmacologic properties. Most recently, the US Food and Drug Administration approved a novel, follow-on basal insulin agent, with more expected to be commercially available in the near future. With the imminent availability of follow-on basal insulin agents, clinicians need to be aware of the potential benefits and concerns in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes. This program will review how follow-on insulin products are developed, manufactured, and receive regulatory approval; evaluate clinical trial data for new and emerging follow-on basal insulin agents; and provide practical information and guidance on how they may be incorporated into clinical practice. While it is unknown how follow-on basal insulins will affect patient outcomes, they have the potential to increase access to treatment among patients with diabetes and reduce healthcare costs.
This CME program will give physicians insight into the ever-growing research in the field of multiple sclerosis. The faculty review MS treatment guidelines and recommendations, including recently updated phenotype descriptions. The experts break down the therapeutic needs in relapsing and progressive MS and analyze novel therapeutics. Emerging therapies are discussed in order to give physicians the most up-to-date information on their options when treating their MS patients. The faculty will guide the learners on creating a personalized approach when developing treatment plans. All these factors will enable physicians to create the best path forward for their current and future multiple sclerosis patients.
Shingles, or herpes zoster, is a common secondary infection caused by a reactivated varicella zoster virus (VZV). More than 95% of immunocompetent individuals aged at least 50 years are seropositive for VZV and are therefore at risk for developing HZ. Age-related increased incidence of herpes zoster and its complications are thought to be related to the decline in cell-mediated immunity. Complications of HZ, which create a significant patient and economic burden, may be neurological, ophthalmological, dermatological, or visceral. Herpes zoster vaccination is essential for the prevention of herpes zoster and its consequences.
AAN 2016: Implementing Disease Modifying Therapies in the Management of Patients with Multiple SclerosisFormat: Medical Meeting Reporter
This continuing medical education program on Multiple Sclerosis will focus on information presented at the 68th Annual American Academy of Neurology Meeting held in April in Vancouver, Canada. The latest advances in Multiple Sclerosis treatment options and methods of slowing disease progression will be discussed by three expert faculty. Recent clinical trial data, including that pertaining to disease monitoring therapies, will be reviewed and related to practice. Methods of creating patient-specific treatment plans utilizing existing data and resources will also be relayed to the learner. This program will allow physicians to better acquaint themselves with the ever evolving science of the Multiple Sclerosis field, in order to more accurately manage their patients with multiple sclerosis and, ultimately, improve patient outcomes.
This Official Elsevier Medical Meeting Reporter will cover dyslipidemia data presented at the American College of Cardiology 65th Annual Scientific Session and Expo held in Chicago, Illinois. The four expert faculty will communicate imperative information for clinical decision-making, as it relates to the comprehensive healthcare team, in both the initiation of treatment and effective communication of therapeutic options for the patient with dyslipidemia. Criteria for statin intolerance and familial hypercholesterolemia will be reviewed in order to ensure physicians are making informed decisions. At the conclusion of this program, learners should be able to create individualized treatment plans incorporating PCSK9 Inhibitors to both reduce risk and improve outcomes in their dyslipidemia patients.
This CME activity will focus on the treatment of multiple sclerosis with recent updates in novel therapeutics. Both new data and long‐term data of available multiple sclerosis therapies show that patients are able to achieve disease activity free status while receiving these therapies. Expert faculty will discuss the treatment of acute relapses in multiple sclerosis. At the conclusion of this program, clinicians will be better equipped to treat relapses in patients with multiple sclerosis.
Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator TherapyFormat: Webcast
The content for this activity is based on the satellite symposium, “Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy” that was presented at the 39th European Cystic Fibrosis Society Conference on June 10, 2016. The emergence of novel targeted agents, that directly correct CFTR loss function alleles, has created new treatment opportunities for patients with cystic fibrosis with advanced disease.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report from AAIC 2016Format: Medical Meeting Reporter
The Alzheimer's Association International Conference® 2016 (AAIC®) annual meeting was held in Toronto, Canada, July 22-28, 2016. AAIC is the world's largest forum for the dementia research community. Researchers, clinicians, care providers, and students from more than 70 countries gather at AAIC to network and discuss the latest dementia study results, theories, and discoveries. In this activity, 2 experts summarize the key learnings from this year’s conference.
This CME Program will highlight information presented at the European Society of Cardiology Congress 2016 held in Rome, Italy on August 27-31, 2016. Didactic presentation in combination with intermittent, interactive panel discussions will provide clinicians with a better understanding of the pathophysiology of hypercholesterolemia, including approaches for prevention and assessment of risk. Three expert faculty will decipher recent clinical trial data and communicate new treatment strategies, including those centered around PCSK9 usage, as well as best practices for patients with dyslipidemia. Discussion about the role and importance of the comprehensive healthcare team will ensue. Upon completing this program, clinicians responsible for the management of patients with dyslipidemia will be better equipped with the most up-to-date information to create tailored treatment plans and optimize patient outcomes.
The pathophysiology of Alzheimer’s disease (AD) involves both amyloid and tau proteins; the exploration of the respective roles of these proteins in neuronal loss and neurodegeneration has important implications for future therapeutic interventions. PET imaging of amyloid and tau plays a critical role in understanding neurodegeneration patterns and clinical manifestations of AD.
ECTRIMS 2016: Optimally Managing Patients with Multiple Sclerosis through Individualized Treatment OptionsFormat: Medical Meeting Reporter
This CME program focuses on content presented during 2016 ECTRIMS Annual Meeting in London, United Kingdom on September 14 – 17, 2016. This activity educates healthcare providers involved in the management of patients with multiple sclerosis (MS) with the goal of presenting the most comprehensive analysis for clinical decision-making. This includes the role of the comprehensive healthcare team in the initiation of therapy, as well as effectively communicating therapeutic decisions to the patient. Faculty members assess patient-specific treatment plans to improve outcomes for patients with multiple sclerosis.
CHEST 2016: Understanding the Role of Targeted Biologic Therapies in the Treatment of Patients with Moderate-to-Severe, Persistent AsthmaFormat: Medical Meeting Reporter
This CME program will focus on information on the clinical decision-making for management of patients with asthma that were presented at the CHEST 2016 Annual Meeting from October 22 - 26, 2016 in Los Angeles, California. The expert faculty of this program will discuss conference highlights and provide a comprehensive analysis of clinical decision-making in patients with asthma. They will discuss the effectiveness of communicating therapeutic decisions with patients. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with asthma.
An Update on Osteoporosis Pathogenesis, Diagnosis, and Treatment is an on-demand webcast CME activity. Osteoporosis is a serious health problem that is increasing with the growth of the aging population. Left untreated, patients with osteoporosis experience considerable morbidity and increased mortality, and their care exacts a large economic burden on the health care system. Although regularly updated clinical guidelines, risk assessment tools, and effective pharmacologic agents are available for the prevention and treatment of osteoporosis, data indicate that patients are not receiving the recommended level of care. In fact, the percentage of patients receiving osteoporosis treatment has declined in recent years even in those with hip fractures.
Strategies for Combating Opioid-Induced Constipation:Targeted Mechanisms to Maintain Pain Control Without CompromiseFormat: Webcast
The content for this activity is based on the satellite symposium, “Strategies for Combating Opioid-Induced Constipation: Targeted Mechanisms to Maintain Pain Control Without Compromise” that was presented at the American Academy of Physical Medicine and Rehabilitation Annual Assembly (AAPM&R) on October 21, 2016. Opioid-induced constipation (OIC) is a common side effect of opioid use and can occur from the outset of opioid therapy. OIC has been reported to interfere with pain management, increase health care costs, decrease work productivity and daily activities, and significantly affect patient quality of life. It can also lead to bowel obstruction. Assessing and managing OIC is important for establishing maximum function for patients. Several pharmacologic approaches, with different mechanisms of action, are available or in development.
ECTRIMS 2016: Utilizing Individualized Treatment Plans to Optimally Manage Patients with Multiple SclerosisFormat: Medical Meeting Reporter
This CME program will focus on the new and emerging therapeutic options for the management of patients with multiple sclerosis (MS) that were discussed at the 2016 ECTRIMS Annual Meeting in London, United Kingdom from September 14 – 17, 2016. This activity will educate healthcare providers about novel techniques and optimal management strategies for their patients with multiple sclerosis. The expert faculty will discuss the science behind new and emerging therapies, the efficacy and safety data supporting new biomarkers, and the role of biomarkers alongside traditional MS treatment options. Upon completion of this CME activity, the multidisciplinary team will be equipped with the information needed to create tailored treatment plans and improve outcomes.
Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic breast cancer (MBC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results have the potential to change clinical practice. In this activity, you will listen to two leading experts in breast cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.
Results from several key clinical trials evaluating new therapeutic approaches for patients with metastatic castration resistant prostate cancer were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11, 2016 in Copenhagen, Denmark. These results indicate that metastatic castration resistant prostate cancer is not a single disease and that biomarkers may play an essential role in deciding on best therapy for your patients. In this activity, you will listen to two leading experts in metastatic castration resistant prostate cancer management and research as they review the key data presented at ESMO 2016 and discuss the implications for current practice and future research.
Potentially practice-changing data from clinical trials in non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11 in Copenhagen, Denmark. These data may not only lead to new treatment options but also help clinicians use existing treatment options more effectively. In this video presentation, two leading experts in the management of NSCLC review key results presented at ESMO 2016 and provide insights on how the results may influence practice today.
The content for this activity is based on the satellite symposium Long-Acting Reversible Contraception: An Important Solution to Reduce Unintended Pregnancy that was presented at The American Congress of Obstetricians and Gynecologists (ACOG) Annual District II Meeting in New York, New York, on October 22, 2016. Despite the availability of numerous contraceptive options, almost half of all pregnancies in the United States are unintended, creating a substantial negative health and socioeconomic burden on women and their families. The most commonly used contraceptives are dependent on adherence and “perfect use” to be efficacious, while long-acting reversible contraceptives (LARCs) offer the lowest failure rates primarily because they are user-independent. Greater use of the highly effective LARCs may provide one solution to the persistent problem of unplanned pregnancies and improve women’s and children’s health. This event was neither sponsored nor endorsed by ACOG.
ESC 2016: Applying Novel Therapeutics to Improve Outcomes in Patients with Pulmonary Arterial HypertensionFormat: Medical Meeting Reporter
This CME program will cover data on current and emerging therapeutic options for treating patients with pulmonary arterial hypertension (PAH) that was presented at the European Society of Cardiology 2016 Annual Congress held in Rome, Italy. The expert faculty will discuss recent clinical trial data on pulmonary arterial hypertension along with ways to integrate new information into daily practice. Clinicians will gain a better understanding of ways to improve outcomes for their patients with PAH by providing the most up-to-date care.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report From CTAD 2016Format: Medical Meeting Reporter
The 9th meeting of Clinical Trials on Alzheimer’s Disease (CTAD) was held in San Diego, California, December 8-10, 2016. CTAD has become one of the most important scientific meetings in the Alzheimer’s disease (AD) area. It brings together today’s global leaders in AD to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of AD treatments. In this activity, 2 experts summarize the key learnings from this year’s conference.
This CME program will focus on new and emerging therapeutic options in the management of patients with dyslipidemia that were discussed at the American Heart Association Annual Congress 2016 in New Orleans, Louisiana. The expert faculty will evaluate clinical trial data and the responsiveness to therapeutic agents. They will discuss the science behind new and emerging therapies, the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options.
New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint InhibitorsFormat: Webcast
The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.
This discussion-based, CME program will feature imperative information for the treatment and management of patients with heart failure presented at the American Heart Association Scientific Sessions 2016 held in Orlando, Florida. Predictors of heart failure, patient assessment techniques and risk-benefit considerations for patients, both in the initiation of treatment and as treatment progresses, will be discussed. The three expert faculty will review newly released clinical trial data, particularly those pertaining to novel targeted therapeutics. Updates on major outcomes trials and the impending effect on clinical practice will be assessed. After participating in this activity, healthcare professionals will gain insight into optimal, personalized treatment and management strategies as well as methods of improving outcomes in patients with heart failure.